Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

Founded on July 3, 1946, SVS celebrates its legacy of supporting vascular surgeons, strengthening the specialty and ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

The US Department of Health and Human Services is requesting revisions to the labels on testosterone replacement therapies ...

WHO's latest report shows that AI is already improving diagnosis, hospital efficiency and patient care across seven countries, but its success depends on strong governance, high-quality data, skilled ...

The Israeli Medical Association has published a position paper that sets boundaries for the growing use of artificial ...

(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...

Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global ...

Penumbra secured FDA clearance and CE Mark for THUNDERBOLT, the first computer-assisted vacuum thrombectomy device for stroke ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

Cardiovascular surgery seems to be just as safe in patients with concomitant multiple sclerosis (MS) as in those without the ...